TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05255016

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: PXL Platinum 330 system + Riboflavin 0.25% TE Solution
Description: Standard-of-care therapy (antifungal drops or fortified antibiotics and empiric antibiotic drops). In addition CXL + Riboflavin 0.25% TE solution.~After topical anesthesia, the surgeon or trained designee will apply topical riboflavin (1 drop every 2 min for 40 min with PESCHKE TE solution \[0.25%\], or longer as needed to assure adequate corneal penetration). At the end of this pre-treatment period, the eye will be examined at the slit lamp with the blue filter for the presence of riboflavin throughout the stroma. When sufficient corneal riboflavin penetration is confirmed, the eye will be aligned under the PXL Platinum 330 light. The correct aperture setting (3 to 12 mm) will be selected for the size of the eye and area needing to be treated (2 mm larger than the maximal ulcer diameter), and the eye will be irradiated at 18 mW/cm2, with pulsed mode (5 seconds on, 5 seconds off) for 10 min, during which time instillation of riboflavin will continue (1 drop every 2 min).

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham CXL + Artificial Tears
Description: Standard-of-care therapy (antifungal drops or fortified antibiotics and empiric antibiotic drops). In addition, for subjects in the sham group, artificial tears (1 drop every 2 min for 40 min) will be administered. after instillation of artificial tears, the eye will be aligned under the PXL Platinum 330 light. The instrument will be kept off and the subject will be kept under the device for 10 min during which time instillation of artificial tears will be performed (1 drop every 2 min) to maintain corneal hydration. The operator will keep track of sham exposure time independently to confirm the actual duration.
Study: NCT06303765

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Practice Resource for Driving After Stroke (PReDAS)
Description: 1. Provision of written copy of PReDAS for occupational therapist to review~2. 1:1 online training session to use the PReDAS (1 hour in length)
Study: NCT05011903

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cross-tailored Dynamic Feedback
Description: Dynamic, technology-delivered weekly feedback on weekend diary self-reports of first-year college student behavior related to alcohol use and related sexual behaviors.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized Feedback Intervention
Description: Technology-delivered personalized feedback on first-year college student behavior related to alcohol use and related sexual behaviors.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized Feedback Intervention
Description: Technology-delivered personalized feedback on first-year college student behavior related to alcohol use and related sexual behaviors.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized Feedback Intervention
Description: Technology-delivered personalized feedback on first-year college student behavior related to alcohol use and related sexual behaviors.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dynamic Feedback on General Health Behaviors
Description: Dynamic, technology-delivered weekly feedback on weekend diary self-reports of first-year college student behavior related to general health behaviors.
Study: NCT06171152

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide Pen Injector [Saxenda]
Description: A weight loss drug that can be taken at home. Liraglutide will be provided as an injectable pen that participants can inject in the stomach, thigh or upper arm. A member of the research team will give you instructions on how to inject liraglutide using the injectable pen and answer any questions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide Pen Injector [Saxenda]
Description: A weight loss drug that can be taken at home. Liraglutide will be provided as an injectable pen that participants can inject in the stomach, thigh or upper arm. A member of the research team will give you instructions on how to inject liraglutide using the injectable pen and answer any questions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medication Diary
Description: Participants will be asked to maintain a medication diary of each dose of liraglutide. A member of the research team will provide a copy of this diary for participants to complete. Participants will be asked to return this medication diary to research staff at each clinic visit.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medication Diary
Description: Participants will be asked to maintain a medication diary of each dose of liraglutide. A member of the research team will provide a copy of this diary for participants to complete. Participants will be asked to return this medication diary to research staff at each clinic visit.
Study: NCT06532838

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Optimized treatment strategies
Description: The optimized strategies based on 6-hour threshold from symptom onset. For malperfused patients with symptom onset within 6 hours, central repair will be performed immediately. Additional stenting will be used in patients with persistent malperfusion. For malperfused patients with symptom onset beyond 6 hours, individualized delayed central repair according to the different types of MPS will be performed after organ function improved and the patient could tolerate central repair.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional treatment strategies
Description: Immediate central repair will be performed for patients with coronary and cerebral malperfusion syndrome. However, for patients with mesenteric and lower extremity malperfusion syndrome, interventional therapy will be administered through fenestration and/or stenting to ﬁrst alleviate organ ischemia. Once the patients had a resolution of organ failure, corrective open aortic repair will be performed.
Study: NCT05476003

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Ultrasound-guided Bilateral superficial cervical plexus block
Description: This nerve block is typically performed in the supine or semi-sitting position, with the head turned slightly away from the side to be blocked to facilitate operator access.~Under strict aseptic condition, the linear ultrasound transducer should be placed on the lateral neck, overlying the sternocleidomastoid muscle at the level of its midpoint (approximately the level of the cricoid cartilage). Once the sternocleidomastoid muscle has been identified, the transducer is moved posteriorly until the tapering posterior edge is positioned in the middle of the screen.~Once the plexus has been identified and using In-Plane approach, the needle is passed from medial to lateral through the skin, platysma and investing layer of deep cervical fascia and the tip is placed adjacent to the plexus.~Following negative aspiration, 1 mL of local anesthetic is injected to confirm the proper injection site. The remainder of the local anesthetic (5ml) is administered to envelop the plexus.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound-guided Bilateral superficial cervical plexus block
Description: This nerve block is typically performed in the supine or semi-sitting position, with the head turned slightly away from the side to be blocked to facilitate operator access.~Under strict aseptic condition, the linear ultrasound transducer should be placed on the lateral neck, overlying the sternocleidomastoid muscle at the level of its midpoint (approximately the level of the cricoid cartilage). Once the sternocleidomastoid muscle has been identified, the transducer is moved posteriorly until the tapering posterior edge is positioned in the middle of the screen.~Once the plexus has been identified and using In-Plane approach, the needle is passed from medial to lateral through the skin, platysma and investing layer of deep cervical fascia and the tip is placed adjacent to the plexus.~Following negative aspiration, 1 mL of local anesthetic is injected to confirm the proper injection site. The remainder of the local anesthetic (5ml) is administered to envelop the plexus.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Midazolam
Description: All patients will be premedicated with Midazolam (0.02mg/Kg).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: All patients will be premedicated with Midazolam (0.02mg/Kg).
Study: NCT05582538

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceralasertib
Description: 240mg orally BD (dose level 0) on days -6 to 0 prior to day 1 cycle 1 and then on days 22 to 28 of cycle 1 and every subsequent cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: 1500 mg i.v. day 1 (q28)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: 100mg/m2 i.v. day 1,8,15 (q28)
Study: NCT04793165

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-hybrid closed-loop system with ARG algorithm
Description: To assess efficacy and safety of non-Hybrid Closed-loop System, without CHO counting
Study: NCT06009770

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: medical device Homing (TecnoBody); medical device Icone (Heaxel)
Description: Rehabilitation activities for PD and MS will be aimed at improving motor performance and balance using a task-oriented approach with Homing system technology; post-stroke patients will perform a home-based upper limb rehabilitation with the iCONE robotic device for robot-assisted neurorehabilitation of the upper limb.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Standard motor exercise training aimed at muscle mobilization and strengthening (MS and PD groups) or to mobilize and enhance motor control of upper limb functions (post-stroke group)
Study: NCT06539936

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Glide
Description: Glide is a myoelectric prosthesis control strategy which enables multifunctional control using a limited set of input EMG signals (as few as two). The Glide control strategy uses the relative contributions of multiple electrode inputs to create a virtual cursor, calculated from a vector summation of multiple EMG channels, to select the type and speed of a movement from a circular map.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Direct Control
Description: Direct Control (DC) is the most common method of control for powered prostheses, which directly links the activity recorded from a single electromyography (EMG) electrode to a prosthesis action. Typically, a pair of EMG electrodes are placed over a pair of agonist/antagonist muscle groups to operate a single DOF (e.g., for transradial amputees the flexor muscles in the forearm may be mapped to the prosthetic hand closing and the forearm extensor muscles mapped to hand opening).
Study: NCT06266494

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Long-Acting silver dressings
Description: Mepilex Transfer Ag
Study: NCT04757012

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: calinange
Description: calinange
Study: NCT05217732

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZX-7101A
Description: tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZX-7101A
Description: tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZX-7101A
Description: tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZX-7101A
Description: tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZX-7101A
Description: tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZX-7101A
Description: tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Tablet
Study: NCT04976920

Intervention type: DIAGNOSTIC_TEST
Intervention: Overture Metabolomics Embryo Selection
Description: Patients will have their embryos selected for transfer based on morphology alone. The embryo transfer outcome will be compared to the metabolomics result to determine the NPV and PPV of metabolomics vs implantation.
Study: NCT06266494

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aloe Vera
Description: Dermaid Aloe Vera

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dalbavancin
Description: 1500mg IV dose
Study: NCT05919797

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone-Bupropion Combination
Description: Participants receive 28 weeks of naltrexone-bupropion weight loss medication during phase two of this study.
Study: NCT06237283

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Early shower
Description: Start shower after drain removal
Study: NCT04837638

Intervention type: BEHAVIORAL
Intervention: Diet
Description: No intervention. Cross-section assessment of the relationship between diet, medication, lifestyle and coronary artery calcification.
Study: NCT05090501

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High Intensity Circuit Training
Description: The participants will execute a 12-exercise High Intensity Circuit Training protocol. Each exercise will have an active part taking 30 seconds, in which exercisers are encouraged to do as many repetitions as possible, and a resting part taking 10 seconds in which the participants rest and are informed of the next exercise. Before and after the 12-exercise routine, the participants rate their affect, arousal and perceived exertion, while using a heart rate monitor and two IMU sensors on their arms and legs.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High Intensity Circuit Training
Description: The participants will execute a 12-exercise High Intensity Circuit Training protocol. Each exercise will have an active part taking 30 seconds, in which exercisers are encouraged to do as many repetitions as possible, and a resting part taking 10 seconds in which the participants rest and are informed of the next exercise. Before and after the 12-exercise routine, the participants rate their affect, arousal and perceived exertion, while using a heart rate monitor and two IMU sensors on their arms and legs.
Study: NCT05071001

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MRI
Description: This assessment will be planned in the year after the consent signAll patients will have one brain MRI performed in Henri Mondor Hospital on a 3T MR unit (Skyra, Siemens, Erlangen). The procedure will include:~1. a 3D-FLAIR imaging~2. a morphometric study based on a 3DT1 MPRAGE gradient echo sequence (TR / TI / TE = 2300/900 /2.9 ms)~3. an analysis of the anatomic connectivity of the patient's brain assessed using a 1.5mm isotopic DTI with a high number of directions (HARDI / 65 directions / b=1500s/mm2).~4. An evaluation of neuronal dysfunction using MR Spectroscopy. Spectroscopic data will be collected using a 2D CSI laser with a short TE technique.~5. Magnetization transfer imaging providing information about integrity of membranes.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MRI
Description: This assessment will be planned in the year after the consent signAll patients will have one brain MRI performed in Henri Mondor Hospital on a 3T MR unit (Skyra, Siemens, Erlangen). The procedure will include:~1. a 3D-FLAIR imaging~2. a morphometric study based on a 3DT1 MPRAGE gradient echo sequence (TR / TI / TE = 2300/900 /2.9 ms)~3. an analysis of the anatomic connectivity of the patient's brain assessed using a 1.5mm isotopic DTI with a high number of directions (HARDI / 65 directions / b=1500s/mm2).~4. An evaluation of neuronal dysfunction using MR Spectroscopy. Spectroscopic data will be collected using a 2D CSI laser with a short TE technique.~5. Magnetization transfer imaging providing information about integrity of membranes.
Study: NCT05760066

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance Training Preconditioning
Description: Resistance training prior to disuse-induced atrophy followed by another period of resistance training

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Activities of daily living prior to disuse-induced atrophy followed by a period of resistance training
Study: NCT04957602

Intervention type: OTHER
Intervention: Blood collection
Description: Blood collection (4\*10ml) before treatment initiation and after the first evaluation (usually 3-4 months after treatment initiation).
Study: NCT06485232

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Universal BCMA CAR-T
Description: Universal BCMA CAR-T

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Universal CD19 CAR-T
Description: Universal CD19 CAR-T
Study: NCT05377359

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Recordings of Hearing Aids with Open Domes
Description: Receiver-in-the-Canal hearing aids will be used which are programmed to the participant's hearing loss and will be coupled to open domes. Recordings will be made of hearing aid output on a head and torso simulator and played back to participants over headphones.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Recordings of Hearing Aids with Closed Domes
Description: Receiver-in-the-Canal hearing aids will be used which are programmed to the participant's hearing loss and will be coupled with closed domes. Recordings will be made of hearing aid output on a head and torso simulator and played back to participants over headphones.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Recordings of Hearing Aids with Novel State 1
Description: Receiver-in-the-Canal hearing aids will be used which are programmed to the participant's hearing loss and will be coupled with the new coupling method in its first state. Recordings will be made of hearing aid output on a head and torso simulator and played back to participants over headphones.
Study: NCT04924192

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB3616 capsules
Description: A CDK4/6 kinase inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB3616 capsules
Description: A CDK4/6 kinase inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib Hydrochloride capsules
Description: A multi-target receptor tyrosine kinase inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan Hydrochloride for Injection
Description: An inhibitor of DNA topoisomerase Ⅰ
Study: NCT05377359

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Recordings of Hearing Aids with Novel State 2
Description: Receiver-in-the-Canal hearing aids will be used which are programmed to the participant's hearing loss and will be coupled with the new coupling method in its second state. Recordings will be made of hearing aid output on a head and torso simulator and played back to participants over headphones.
Study: NCT06375954

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic biliary drainage
Description: Decompression of the bile duct by endoscopic aproach.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic biliary drainage
Description: Decompression of the bile duct by endoscopic aproach.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Self-expandable metallic stent (SEMS)
Description: Self-expandable metallic stent (SEMS) deployment:~* Covering: Uncovered or Partially Covered. Non covered if gallbladder is present.~* Size: 10x40mm or 10x60mm or 10x80mm.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lumen-apposing metal stent (LAMS) and double-pigtail plastic stent (DPPS)
Description: Lumen-apposing metal stent (LAMS) with coaxial double-pigtail plastic stent (DPPS) deployment:~* LAMS size: 6x8mm or 8x8mm. Consider 10x10mm if bile duct \> 18mm.~* DPPS size: 7Fr x 3-7cm.
Study: NCT06617013

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Discontinuation of GERD therapy
Description: GERD therapy will be discontinued at time of enrollment.
Study: NCT06672198

Intervention type: PROCEDURE
Intervention: ERAC protocol
Description: our study aimed to evaluate pre-peri-post operative practices in women who underwent elective cesarean section (CS) according to the ERAC protocol. In this context, this study aimed to describe the implementation status of the recommendations regarding the ERAC protocol in CS operations, to identify the missing aspects of the ERAC protocol and to raise awareness about its benefits.
Study: NCT06485232

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Universal BCMA CAR-T; Universal CD19 CAR-T
Description: Universal BCMA CAR-T; Universal CD19 CAR-T
Study: NCT05903560

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: endovascular recanalization via radial approach
Description: Patients with basilar artery occlusion within 24 hours of onset will be chosen to receive endovascular recanalization via radial approach

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: endovascular recanalization via femoral approach
Description: Patients with basilar artery occlusion within 24 hours of onset will be chosen to receive endovascular recanalization via femoral approach
Study: NCT04149821

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Umbralisib
Description: * Lead-in cycle of 28 days (Cycle -1) of umbralisib monotherapy, 800mg oral daily~* Continued 800mg oral daily dosing in all subsequent cycles (combination therapy cycles 1-6, then continued monotherapy cycle 7 and beyond)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Umbralisib
Description: * Lead-in cycle of 28 days (Cycle -1) of umbralisib monotherapy, 800mg oral daily~* Continued 800mg oral daily dosing in all subsequent cycles (combination therapy cycles 1-6, then continued monotherapy cycle 7 and beyond)
Study: NCT06619834

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Financial Navigation and Peer Support
Description: A combined intervention of technology-supported financial navigation and peer support: A professional financial navigator from TailorMed will use the software to assist participants in exploring options to reduce their specific economic barriers to treatment and care, and non-medical social risks. Participants will also be matched with a Peer Supporter to help improve the participants\&#39; diabetes self-management.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Financial Navigation Only
Description: A professional financial navigator from TailorMed will use the software to assist participants in exploring options to reduce their specific economic barriers to treatment and care, and non-medical social risks.
Study: NCT05840497

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance exercise
Description: The intervention group will train 3 times per week (30 minutes with 15 min warm-up). The resistance exercise is described as the voluntary contraction of the skeletal muscle of a particular muscle group against some type of resistance, using light weights, elastic bands or the weight of the body itself.~Patients will be offered online sessions, they will receive a document with recommendations and a link to the videos with instructions.~.